Flow cytometry showed that CD4+IFN-γ+ (p = 0.521) and CD4+IL-4+ (p = 0.414) were not statistically different between the GVHD group and the belimumab-treated group, then belimumab treated group had shown a tendency to decrease populations of CD4+IFN-γ+ and CD4+IL-4 (Figure 3A). The gene discussed is IL4; the disease is graft versus host disease.